Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

GOVARDHANAN NAGAIAH

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1386736585
CMS profile
1171310
Location
GOODYEAR, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$37,961.35

193 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
Dova Pharmaceuticals $14,662.50 12
GENZYME CORPORATION $12,336.52 14
PFIZER INC. $3,829.99 6
EMD Serono, Inc. $2,076.64 3
Regeneron Healthcare Solutions, Inc. $1,120.42 3
Janssen Biotech, Inc. $999.02 8
Celgene Corporation $262.66 8
E.R. Squibb & Sons, L.L.C. $225.86 8
AstraZeneca Pharmaceuticals LP $212.60 11
Genentech USA, Inc. $168.20 9
Seagen Inc. $156.61 10
Incyte Corporation $136.85 7
Lilly USA, LLC $105.80 6
Bayer HealthCare Pharmaceuticals Inc. $101.79 5
Merck Sharp & Dohme Corporation $93.42 5
Exelixis Inc. $86.22 4
Amgen Inc. $79.71 6
Pharmacyclics LLC, An AbbVie Company $76.87 4
Myovant Sciences Inc. $69.95 4
AbbVie Inc. $69.16 3
Ipsen Biopharmaceuticals, Inc $67.14 3
TG THERAPEUTICS, INC. $62.85 1
Boehringer Ingelheim Pharmaceuticals, Inc. $59.83 2
Kyowa Kirin, Inc. $59.13 3
AMAG Pharmaceuticals, Inc. $58.56 3
Clovis Oncology, Inc. $57.68 3
Gilead Sciences, Inc. $52.03 3
Alnylam Pharmaceuticals Inc. $42.62 2
SANOFI-AVENTIS U.S. LLC $41.17 2
PUMA BIOTECHNOLOGY, INC. $40.32 2
JAZZ PHARMACEUTICALS INC. $38.71 2
TerSera Therapeutics LLC $38.69 2
Daiichi Sankyo Inc. $38.20 2
Astellas Pharma US Inc $36.14 2
Karyopharm Therapeutics Inc. $35.43 2
GlaxoSmithKline, LLC. $34.22 2
Blueprint Medicines Corporation $31.99 2
Epizyme, Inc., $30.97 2
Global Blood Therapeutics, Inc. $29.49 2
MorphoSys, US Inc. $29.30 2
ARRAY BIOPHARMA INC $29.12 2
Rigel Pharmaceuticals, Inc. $19.25 1
Eisai Inc. $19.01 1
Coherus Biosciences Inc. $17.64 1
MACROGENICS, INC. $17.46 1
Secura Bio, Inc. $16.55 1
Aveo Pharmaceuticals, Inc. $16.13 1
Servier Pharmaceuticals LLC $15.57 1
Acrotech Biopharma LLC $14.99 1
BeiGene USA, Inc. $13.54 1
G1 Therapeutics, Inc. $13.49 1
Novartis Pharmaceuticals Corporation $13.34 1

Page 3 of 4; records 101–150 of 193 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

GOVARDHANAN NAGAIAH

NPI 1386736585 · CMS profile ID 1171310

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

GOODYEAR, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 193 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1386736585?year=2021&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
GOVARDHANAN NAGAIAH, NPI 1386736585, CMS profile ID 1171310. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 193 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1386736585?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). GOVARDHANAN NAGAIAH, NPI 1386736585, CMS profile ID 1171310. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 193 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1386736585?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
GOVARDHANAN NAGAIAH, NPI 1386736585, CMS profile ID 1171310, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 193 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1386736585?year=2021&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

193 matching records · $37,961.35 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 193 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 193.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Dova Pharmaceuticals $114.1206/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849749103 CMS
Dova Pharmaceuticals $2,850.0006/22/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849749105 CMS
Celgene Corporation $15.6106/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783699065 CMS
Genentech USA, Inc. $12.4606/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835915605 CMS
Daiichi Sankyo Inc. $19.3206/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836300297 CMS
GlaxoSmithKline, LLC. $14.0806/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802882173 CMS
GENZYME CORPORATION $61.7206/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843553735 CMS
GENZYME CORPORATION $3,255.0006/17/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843553737 CMS
GENZYME CORPORATION $119.2806/17/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843553739 CMS
Global Blood Therapeutics, Inc. $13.4806/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835341027 CMS
Pharmacyclics LLC, An AbbVie Company $23.1406/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 781013341 CMS
Janssen Biotech, Inc. $15.3006/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788183481 CMS
AstraZeneca Pharmaceuticals LP $23.0806/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829424885 CMS
Celgene Corporation $21.8006/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783699057 CMS
AMAG Pharmaceuticals, Inc. $20.9206/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 847693645 CMS
Gilead Sciences, Inc. $11.9206/01/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845877015 CMS
E.R. Squibb & Sons, L.L.C. $17.3305/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783520799 CMS
Amgen Inc. $11.9905/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826342827 CMS
Lilly USA, LLC $21.8705/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819173643 CMS
Epizyme, Inc., $16.6405/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832341949 CMS
Regeneron Healthcare Solutions, Inc. $15.3305/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809607803 CMS
Alnylam Pharmaceuticals Inc. $17.8305/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 828518563 CMS
Astellas Pharma US Inc $14.5605/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821464541 CMS
E.R. Squibb & Sons, L.L.C. $14.3905/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783520793 CMS
Celgene Corporation $125.0005/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 853637741 CMS
PFIZER INC. $14.8605/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832713855 CMS
Gilead Sciences, Inc. $19.2705/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848246325 CMS
Lilly USA, LLC $16.4705/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819108897 CMS
PFIZER INC. $1,500.0005/14/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833395477 CMS
Janssen Biotech, Inc. $14.7005/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788183487 CMS
Seagen Inc. $15.6005/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832145585 CMS
Genentech USA, Inc. $19.4705/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835915617 CMS
Janssen Biotech, Inc. $13.5905/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788183489 CMS
Seagen Inc. $12.3505/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832145589 CMS
AbbVie Inc. $23.3405/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795272583 CMS
GlaxoSmithKline, LLC. $20.1405/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802971613 CMS
Ipsen Biopharmaceuticals, Inc $22.9005/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 841911249 CMS
Genentech USA, Inc. $18.1105/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835915615 CMS
JAZZ PHARMACEUTICALS INC. $20.2905/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845585231 CMS
Karyopharm Therapeutics Inc. $21.2104/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845785115 CMS
Clovis Oncology, Inc. $20.9304/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 790253969 CMS
Lilly USA, LLC $21.9604/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819173639 CMS
Astellas Pharma US Inc $21.5804/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821464535 CMS
Janssen Biotech, Inc. $19.4204/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788183491 CMS
Incyte Corporation $21.4604/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835528989 CMS
Myovant Sciences Inc. $18.0504/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834974863 CMS
Exelixis Inc. $25.3604/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838868705 CMS
Lilly USA, LLC $21.7904/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819151666 CMS
GENZYME CORPORATION $17.8304/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843553693 CMS
Bayer HealthCare Pharmaceuticals Inc. $16.0204/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 789122181 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $66,781.92 249
PY2020 $30,781.63 100
PY2021 $37,961.35 193
PY2022 $35,412.30 181
PY2023 $37,048.78 220
PY2024 $9,094.03 217
PY2025 $4,699.74 133

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $211,255.00 7
PY2024 Principal investigator $197,185.15 38
PY2023 Principal investigator $150,571.76 44
PY2022 Principal investigator $310,184.42 140
PY2021 Principal investigator $166,559.34 50
PY2020 Principal investigator $99,527.66 56
PY2019 Recipient $18,403.00 1
PY2019 Principal investigator $192,629.40 43

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

7 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $62,441.52 05/30/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Untreated Triple-Negative or Hormone Receptor low/HER2-negative Breast Cancer (TROPION Breast04) No dispute reported 06/30/2026 1185539469
Principal investigator 1 AstraZeneca Pharmaceuticals LP $77,897.68 04/30/2025 Non-covered Recipient Entity
ARIZONA ONCOLOGY
A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Untreated Triple-Negative or Hormone Receptor low/HER2-negative Breast Cancer (TROPION Breast04) No dispute reported 06/30/2026 1185539467
Principal investigator 1 TOLMAR, INC. $1,200.00 04/11/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH, LLC
TOL2506A No dispute reported 06/30/2026 1237321475
Principal investigator 1 AstraZeneca Pharmaceuticals LP $55,823.80 02/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Untreated Triple-Negative or Hormone Receptor low/HER2-negative Breast Cancer (TROPION Breast04) No dispute reported 06/30/2026 1185539465
Principal investigator 1 AstraZeneca Pharmaceuticals LP $510.00 01/15/2025 Non-covered Recipient Entity
TMC HEALTH CANCER CENTER WILMOT
A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan?(DatoDXd) With or Without Durvalumab Versus Investigators Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy No dispute reported 06/30/2026 1185539463
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $382.00 01/07/2025 Non-covered Recipient Entity
Us Oncology Res Llc
Randomized, Open-Label, Phase 3 Trial of Nivolumab plus Ipilimumab or Nivolumab plus Platinum-Doublet Chemotherapy versus Platinum-Doublet Chemotherapy in Early Stage Non Small Cell Lung Cancer No dispute reported 06/30/2026 1235992205
Principal investigator 1 AstraZeneca Pharmaceuticals LP $13,000.00 01/03/2025 Non-covered Recipient Entity
THE US ONCOLOGY NETWORK
A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan?(DatoDXd) With or Without Durvalumab Versus Investigators Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy No dispute reported 06/30/2026 1185539471